The hepatitis C (HCV) market was white hot in 2011 and through the
beginning of 2012, but investors have gotten the message that new HCV
drugs are not going to rival cancer and cardiovascular drugs for
profits. In this interview with The Life Sciences Report,
analyst John Tucker of Sagient Research discusses a handful of stocks
that could benefit from new, patient-friendly HCV therapies with enough
revenue to propel shares upward.